THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to prior authorization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
| KARA SMITH | — |
Health Issues HCR
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation, inclusion of PBM reform and other health policies; Issues relating to implementation of the No Surprises Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDAN DEVINE | — |
| KATHRYN GALLAGHER | — |
| CHRISTOPHER HARTMANN | — |
| JULIEN MITCHELL RELFE | — |
| KARA SMITH | — |
Defense DEF
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDAN DEVINE | — |
| CHRISTOPHER HARTMANN | — |
| JULIEN MITCHELL RELFE | — |
Pharmacy PHA
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENDAN DEVINE | — |
| KATHRYN GALLAGHER | — |
| CHRISTOPHER HARTMANN | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
| KARA SMITH | — |
Labor Issues/Antitrust/Workplace LBR
Issues related to competition in the health care marketplace.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN GALLAGHER | — |
| JULIEN MITCHELL RELFE | — |
| KRISTINA KAYE WEGER New | Health Policy and Communications Director, U.S. Rep. Blaine Luetkemeyer (MO); Intern, U.S. Sen. Roy Blunt (MO) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.